Table 1.
The treatment protocols based on the stage of disease
| Treatment | Number of patients | ||||
|---|---|---|---|---|---|
| Stage I. | Stage II. | Stage III. | Stage IV. | All | |
| ABVD/EBVD + RT | 3 | 52 | 9 | 8 | 72 (51.5%) |
| ABVD/EBVD – RT | 0 | 5 | 9 | 9 | 23 (16.5%) |
| COPP/ABVD + RT | 1 | 3 | 12 | 0 | 16 (11%) |
| COPP/ABVD – RT | 0 | 0 | 5 | 2 | 7 (5%) |
| CVPP + RT | 1 | 6 | 4 | 1 | 12 (9%) |
| CVPP – RT | 1 | 0 | 2 | 0 | 3 (2%) |
| Other | 1 | 2 | 4 | 0 | 7 (5%) |
A(E)BVD: adriamycin (epirubicin), bleomycin, vinblastine and dacarbazine; CV(O)PP: cyclophosphamide, vinblastine [vincristine], procarbazine and prednisolone; COPP/ABV: cyclophosphamide, vincristine, procarbazine, prednisolone/adriamycin, bleomycin and vinblastine; Other protocols include MOPP: mustargen, vincristine, procarbazin, prednisolone, OEPA: vincristine, etoposide, prednisone, and doxorubicin